UNSPSC 51183612: Pancreatic extract

This classification denotes extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific uncharacterized factors or proteins with specific activities.

UNSPSC 51183612 Pancreatic extract is a Commodity code that, based on recent state and local solicitation activity, encompasses generic multi-source pharmaceuticals and over-the-counter products distributed across participating government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicited manufacturers and distributors to supply comprehensive pharmaceutical product lines with specific National Drug Codes, including generic formulations and OTC items, to be distributed through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and offer flexible pricing structures including flat price, net price formats, or WAC-minus pricing. State and local health and human services agencies, corrections departments, and other government health facilities are the primary end users of products procured under this code through cooperative purchasing vehicles.

The MMCAP RFP posted January 20, 2026, with proposals due March 26, 2026, targets multiple participating states including Oregon alongside Minnesota, demonstrating geographic scope across the upper Midwest and Pacific Northwest. Evaluation weighting heavily emphasizes price competitiveness at 75 percent, with the remaining 25 percent distributed among fixed pricing terms, administrative fee compliance, EDI capability, and pricing flexibility commitment. Contract awards become effective July 1, 2026, with products required to be available in the marketplace by May 15, 2026. The contract term spans two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendor amendments align with existing agreement expirations through June 30, 2028. Performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials. Vendors must maintain comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability, and all products must meet FDA requirements with minimum expiration dates of one year from manufacture and six-month shelf life.